Lack of CD27 in myeloma delineates different presentation and outcome.
CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%). The prognostic impact of CD27 expression was evaluated in 42 patients with de novo MM. Overall survival was 92% at 3 years in CD27(+) vs. 50% in CD27(-) MM (P = 0.017). CD27 expression seems to delineate two important subsets of MM with different presenting features and clinical outcomes.
Moreau
Philippe
P
Department of Clinical Haematology, Hôtel Dieu, France.
Robillard
Nelly
N
Jégo
Gaétan
G
Pellat
Catherine
C
Le Gouill
Steven
S
Thoumi
Soraya
S
Avet-Loiseau
Hervé
H
Harousseau
Jean-Luc
JL
Bataille
Régis
R
D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000628:therapy; D010950:Plasma Cells / Q000276:immunology; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000097:blood*
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7